Genelux Corporation

Healthcare · Biotechnology · United States

Last price 2.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 94.11M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product...